• FDA gives emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatment

    FDA gives emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatment

    The Food and Drug Administration on Monday issued an emergency clearance to Eli Lilly’s experimental COVID-19 antibody treatment. The drug, praised by President Trump, was proven effective in
  • Drugmaker touts ‘major breakthrough’ with coronavirus inhaler treatment

    Drugmaker touts ‘major breakthrough’ with coronavirus inhaler treatment

    British drugmaker Synairgen says it has developed a new coronavirus inhaler treatment that helps prevent hospitalized patients from getting seriously ill. The company announced results Monday from a small clinical trial of its drug known as SNG001 that it called a potential “major breakthrough” in the fight against the bug, even though the study reportedly …
  • Gilead developing inhaled remdesivir usable outside of hospitals

    Gilead developing inhaled remdesivir usable outside of hospitals

    Gilead Sciences is developing easier-to-administer versions of its antiviral treatment remdesivir for COVID-19 that could be used outside of hospitals, including ones that can be inhaled, after trials showed moderate effectiveness for the drug given by infusion. Remdesivir is the only drug so far that has been shown to help patients with COVID-19, but Gilead …
  • Gilead study finds remdesivir helps treat some coronavirus patients

    Gilead study finds remdesivir helps treat some coronavirus patients

    Gilead Sciences’ antiviral drug remdesivir showed signs of helping certain coronavirus patients in a study showing better results from a shorter course of treatment, the company said Monday. People with moderate COVID-19 pneumonia who took a five-day treatment of remdesivir were 65 percent more likely to show “clinical improvement” at day 11 than people who …
  • AstraZeneca may expose coronavirus vaccine participants to pathogen

    AstraZeneca may expose coronavirus vaccine participants to pathogen

    The chief executive of AstraZeneca, which is developing a leading coronavirus vaccine with Oxford University, said it is too early to deliberately expose trial participants to the pathogen, but it may become an option if ongoing tests hit a snag. The British drugmaker last week started phase 2 and 3 trials of the vaccine, looking …
  • Coronavirus patients eagerly join Gilead Sciences drug study

    Coronavirus patients eagerly join Gilead Sciences drug study

    The new coronavirus made Dr. Jag Singh a patient at his own hospital. His alarm grew as he saw an X-ray of his pneumonia-choked lungs and colleagues asked his wishes about life support while wheeling him into Massachusetts General’s intensive care unit. When they offered him a chance to help test remdesivir, an experimental drug …